PUBLIC COMPANY
save$CUECue Biopharma, Inc.
$CUEBoston, MA, USupdated 4mo ago
community read0 votes
pipeline
3
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(3)
pipeline depth3 products
1Preclinical1Phase 11Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Insider activity
source: SEC Form 4routine RSU / option mechanics (3)
- Apr 9, 26grantSandercock Colin · SVP, GENERAL COUNSEL200,000 sh
- Apr 9, 26grantWarren Lucinda · CHIEF BUSINESS OFFICER250,000 sh
- Apr 9, 26grantBaker Daniel G. · CHIEF DEVELOPMENT OFFICER100,000 sh
🐶 Hiring Signal
News
- Chutes & Ladders—Travere chief makes way for former Amicus CEOTravere Therapeutics CEO Eric Dube, Ph.D., is stepping down after overseeing the launch of the rare kidney disease drug Filspari.fiercebiotech · 10d ago
- An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slideAlkermes’ results heightened anticipation for a coming readout in 2027. Elsewhere, AbbVie leaned into AI drug discovery and the FDA expanded use of Eli Lilly’s breast cancer pill.biopharma_dive · 12d ago
Data sources
last refreshed 5m ago
Found something off?
comments(0)
5-min edit window · permanent after that